ArticleBriefings in bioinformatics2025
Advancing promiscuous aggregating inhibitor analysis with intelligent machine learning classification.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Toward Predicting Solubility of Arbitrary Solutes in Arbitrary Solvents: Prediction of Density and Refractive Index Using Machine Learning Algorithms with Global Sensitivity Analysis.Organic process research & development · 2026Article
- A Comparative Study of Deep Learning and Classical Modeling Approaches for Protein-Ligand Binding Pose and Affinity Prediction in Coronavirus Main Proteases.Journal of chemical information and modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Small molecules have been playing a crucial role in drug discovery; however, some exhibit nonspecific inhibitory effects during hit screening due to the formation of colloidal aggregators. Such false positives often lead to significant research costs and time investment. Therefore, to identify potential aggregating compounds efficiently and accurately at an early stage of drug discovery, we employed several machine learning techniques to develop classification models for identifying promiscuous aggregating inhibitors. Using a training dataset of 10 000 aggregators and 10 000 nonaggregators, models were trained by combining four different molecular representations with various machine learning algorithms. We found that the best-performing model is the one that employs path-based FP2 fingerprints in conjunction with the cubic support vector machine algorithm, which achieved the highest accuracy and area under the receiver operating characteristic curve values for both the validation and test datasets while maintaining high sensitivity and specificity levels (>0.93). Additionally, we have proposed a new model interpretation method, global sensitivity analysis (GSA), to complement the well-recognized SHapley Additive exPlanations analysis. Several comparative studies have shown that GSA is a time-efficient and accurate approach for identifying crucial descriptors that contribute to model prediction, especially in the scenario where the dataset contains a substantial number of data entries with a limited set of descriptors. Our models as well as GSA findings can provide useful guidance on screening library design to minimize false positives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.